Su YM, Jin KM, Wang HW, Wang YY, Yan XL, Wang K, Li J, Xu D, Xing BC. Survival prediction of colorectal liver metastases underwent surgical resection after neoadjuvant chemotherapy: Tumor response combined with the genetic and morphological evaluation score,Eur J Surg Oncol,Eur J Surg Oncol. 2024 Oct 21:108777. doi: 10.1016/j.ejso.2024.108777. Online ahead of print.

Zheng K, Zhu X, Xu L, Cao G, Niu C, Yan X, Xu D, Liu W, Bao Q, Wang L, Wang K, Xing B, Wang X. Efficacy and safety of hepatic arterial infusion chemotherapy combined with fruquintinib and tislelizumab for patients with microsatellite stable colorectal cancer liver metastasis following failure of multiple-line therapy,Front Oncol,Front Oncol. 2024 Aug 20;14:1420956. doi: 10.3389/fonc.2024.1420956. eCollection 2024.

Xing T, Li L, Chen Y, Ju G, Li G, Zhu X, Ren Y, Zhao J, Cheng Z, Li Y, Xu D, Liang J. Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma,Cell Rep Med,Cell Rep Med. 2023 Nov 21;4(11):101264. doi: 10.1016/j.xcrm.2023.101264. Epub 2023 Nov 7.

Liu J, Zhu X, Pan Y, Zhong J, Jin R, Zheng X, Zhang W, Hu K, Ma J, Shi X, Liu H, Yang X, Xu D, Ma C, Chen J, Wang D, Wang X, Li Z, Zhao L, Zhang L, Li T, Liu F, Tan G, Xing B, Zhao H, Zeng Y, Zhang S, Zhang L, Zhou L, Song T, Yang W, Liang X, Xiang B, Xu L, Sun H, Wang K. Prognoses of Patients Treated With Surgical Therapy Versus Continuation of Local-Plus-Systemic Therapy Following Successful Down-Staging of Intermediate-Advanced Hepatocellular Carcinoma: A Multicenter Real-World Study,Oncologist,Oncologist. 2024 Apr 4;29(4):e487-e497. doi: 10.1093/oncolo/oyad277.

Liu W, Jin KM, Zhang MH, Bao Q, Liu M, Xu D, Wang K, Xing BC. Recurrence Prediction by Circulating Tumor DNA in the Patient with Colorectal Liver Metastases After Hepatectomy: A Prospective Biomarker Study,Ann Surg Oncol,Ann Surg Oncol. 2023 Aug;30(8):4916-4926. doi: 10.1245/s10434-023-13362-1. Epub 2023 May 23.

Pan Y, Zhu X, Liu J, Zhong J, Zhang W, Shen S, Jin R, Liu H, Ye F, Hu K, Xu D, Zhang Y, Chen Z, Xing B, Zhou L, Chen Y, Zeng Y, Liang X, Kuang M, Song T, Xiang B, Wang K, Sun H, Xu L; China Liver Cancer Study Group Young Investigators (CLEAP). Systemic therapy with or without transcatheter intra-arterial therapies for unresectable hepatocellular carcinoma: a real-world, multi-center study,Front Immunol,Front Immunol. 2023 Apr 26;14:1138355. doi: 10.3389/fimmu.2023.1138355. eCollection 2023.

Wang L, Wang H, Cui Y, Liu M, Jin K, Xu D, Wang K, Xing B. Sintilimab plus Lenvatinib conversion therapy for intermediate/locally advanced hepatocellular carcinoma: A phase 2 study,Front Oncol,Front Oncol. 2023 Feb 16;13:1115109. doi: 10.3389/fonc.2023.1115109. eCollection 2023.

Su YM, Liu W, Yan XL, Wang LJ, Liu M, Wang HW, Jin KM, Bao Q, Wang K, Li J, Xu D, Xing BC. Five-year survival post hepatectomy for colorectal liver metastases in a real-world Chinese cohort: Recurrence patterns and prediction for potential cure,Cancer Med,Cancer Med. 2023 Apr;12(8):9559-9569. doi: 10.1002/cam4.5732. Epub 2023 Feb 27.

Bao X, Wang K, Liu M, Li B, Wang H, Jin K, Yan X, Zhang H, Bao Q, Xu D, Wang L, Liu W, Wang Y, Li J, Liu L, Fang W, Xing B. Characterization of Genomic Alterations in Colorectal Liver Metastasis and Their Prognostic Value,Front Cell Dev Biol,Front Cell Dev Biol. 2022 Jul 4;9:760618. doi: 10.3389/fcell.2021.760618. eCollection 2021.

Xu D, Zhu HB, Wang YY, Jin KM, Yan XL, Li J, Wang K, Xing BC. Perioperative second-line chemotherapy is beneficial for resectable liver metastases that occur during or early after adjuvant chemotherapy for colorectal cancer,Int J Colorectal Dis,Int J Colorectal Dis. 2022 Apr;37(4):805-814. doi: 10.1007/s00384-022-04111-z. Epub 2022 Feb 21.

Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Long disease-free interval diminishes the prognostic value of primary tumor stage for patients with colorectal cancer liver metastases,HPB (Oxford),HPB (Oxford). 2022 May;24(5):737-748. doi: 10.1016/j.hpb.2021.10.001. Epub 2021 Oct 23.

Xu D, Wang YY, Yan XL, Li J, Wang K, Xing BC. Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases,J Gastrointest Oncol,J Gastrointest Oncol. 2021 Aug;12(4):1498-1508. doi: 10.21037/jgo-21-82.

Wang K, Liu M, Wang HW, Jin KM, Yan XL, Bao Q, Xu D, Wang LJ, Liu W, Wang YY, Li J, Liu LJ, Zhang XY, Yang CH, Jin G, Xing BC. Mutated DNA Damage Repair Pathways Are Prognostic and Chemosensitivity Markers for Resected Colorectal Cancer Liver Metastases,Front Oncol,Front Oncol. 2021 Mar 31;11:643375. doi: 10.3389/fonc.2021.643375. eCollection 2021.

Liu JM, Wang YY, Liu W, Xu D, Wang K, Xing BC. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy,Int J Colorectal Dis,Int J Colorectal Dis. 2021 Apr;36(4):767-778. doi: 10.1007/s00384-020-03828-z. Epub 2021 Jan 9.

Xu D, Xing BC. Quality over quantity: a necessary path for clinical research transformation in China,Hepatobiliary Surg Nutr,Hepatobiliary Surg Nutr. 2020 Oct;9(5):684-686. doi: 10.21037/hbsn-2020-5.

Xu D, Yan XL, Liu JM, Li J, Xing BC. The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy,J Cancer,J Cancer. 2020 Aug 27;11(21):6256-6263. doi: 10.7150/jca.47911. eCollection 2020.